VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 20, 2005--Inflazyme Pharmaceuticals Ltd. (TSX:IZP) announced today it is proceeding with its Phase IIb clinical study in Q1 2006 with IPL512,602, an oral, once a day, anti-inflammatory medication for the control of asthma. The Phase IIb study is an international study being undertaken in the US, Russia and several Central European countries. Dr. Kevin Mullane, Inflazyme’s President and CEO, stated “We are pleased to be taking IPL512,602 into a Phase IIb clinical study in persistent asthma in Q1 2006. We have selected a CRO capable of executing on this key study.” IPL512,602 showed statistical significance in an earlier Phase IIa clinical study in patients with mild asthma on clinical endpoints that are recognized markers of asthma control including quality of life measures and decreased need for rescue medication. These efficacy endpoints are incorporated into the Phase IIb study design, and are based on feedback received from the FDA.
